Holding(s) in Company

RNS Number : 8356C

Circassia Pharmaceuticals Plc

20 March 2014

 



 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii				Circassia Pharmaceuticals Plc Sedol BJVD3B2
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights					√
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
An event changing the breakdown of voting rights
Other (please specify):	Shares admitted to trading on London Stock Exchange				√
3. Full name of person(s) subject to the notification obligation: iii		¹Lansdowne Partners Limited being the General Partner of Lansdowne Partners Limited Partnership ²Lansdowne Partners International Limited
4. Full name of shareholder(s)  (if different from 3.):iv		Morstan Nominees Ltd
5. Date of the transaction and date on which the threshold is crossed or reached: v		18/03/2014
6. Date on which issuer notified:		20/03/2014
7. Threshold(s) that is/are crossed or reached: vi, vii		5%

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of shares if possible using the ISIN CODE

Situation previous to the triggering transaction

Resulting situation after the triggering transaction

Number of Shares

Number of Voting Rights

Number of shares

Number of voting rights

% of  voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Ordinary Shares

10,333,750

10,333,750

12,775,679

6.82%

GB00BJVD3B28

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument

Expiration date xiii

Exercise/ Conversion Period xiv

Number of voting rights that may be acquired if the instrument is exercised/ converted.

% of voting rights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financial instrument

Exercise price

Expiration date xvii

Exercise/ Conversion period xviii

Number of voting rights instrument refers to

% of voting rights xix, xx

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

12,775,679

6.82%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi
Lansdowne Partners International Limited is the parent undertaking of Lansdowne Partners Limited.
Proxy Voting:
10. Name of the proxy holder:		Lansdowne Partners Limited
11. Number of voting rights proxy holder will cease to hold:
12. Date on which proxy holder will cease to hold voting rights:
13. Additional information:	Based on total voting rights of 187,422,379
14. Contact name:	Julien Cotta Chief Financial Officer
15. Contact telephone number:	[phone]

 

END

 

 

HOLURONRSBAOUAR